BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novo Nordisk, Inc. (NVO): Transaction in Own Shares


6/3/2009 12:09:07 PM

BAGSVAERD, DENMARK--(Marketwire - June 02, 2009) - Status regarding Novo Nordisk's holding of own shares


In continuation of the company's announcement dated 29 January 2009 concerning Novo Nordisk's share repurchase programme, and pursuant to Section 29 of the Danish Securities Trading Act, this is to report that as of today, Novo Nordisk A/S (NYSE: NVO) and its wholly-owned affiliates own more than 5% of the total share capital in Novo Nordisk A/S.

As per 2 June, Novo Nordisk A/S and its wholly-owned affiliates own 31,741,925 of its own B shares of DKK 1, corresponding to a total nominal value of DKK 31,741,925 or 5.0% of the total share capital.

Novo Nordisk is a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs more than 27,900 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit novonordisk.com.

Further information:

Company Announcement no 31 / 2009


This announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.



Copyright © Hugin AS 2009. All rights reserved.


Media:

Elin K Hansen
Tel: (+45) 4442 3450
Email Contact

In North America:
Sean Clements
Tel: (+1) 609 514 8316
Email Contact

Investors:

Mads Veggerby Lausten
Tel: (+45) 4443 7919
Email Contact

Kasper Roseeuw Poulsen
Tel: 4442 4471
Email Contact

In North America:
Hans Rommer
Tel: (+1) 609 919 7937
Email Contact



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES